Skip to main content
. Author manuscript; available in PMC: 2015 Oct 21.
Published in final edited form as: Vaccine. 2014 Sep 13;32(46):6138–6145. doi: 10.1016/j.vaccine.2014.08.070

Figure 1. ABX196 demonstrates an agonist and adjuvant activity in mice.

Figure 1

(A) α-Galcer, PBS-57 and ABX196 [(2S, 3S, 4R)-2-tetracosanoylamino-1-O-(6-Acetamido-α-D galactopyranosyl) octadecane-1,3,4-triol] structures.

(B) Mice (3 per group) received by I.M. injection PBS, or empty liposome or α-Galcer (1µg) or PBS-57 (1µg) or ABX196 (1µg). Sera were collected before and 12, 24 and 48 hours post injection. IFN-γ level was assessed by cytometric bead array (CBA).

(C) Mice (3 per group) received by I.M. injection PBS, or empty liposome or α-Galcer (1µg) or PBS-57 (1µg) or ABX196 (1µg). Sera were collected before and 2, 4, 12 and 24 hours post injection. IL-4 level was assessed by cytometric bead array (CBA).

(D) Mice (6 per group) received by I.M. injection, PBS, OVA (50µg) or α-Galcer (KRN7000) (1µg) or ABX196 (1µg) or PBS-57 (1µg) or OVA (50µg) mix with α-Galcer or with PBS-57 or with ABX196 at three doses (1ng, 100ng and 1µg). Fourteen days later, mice received (I.V. injection) a mix of irrelevant peptide and SIINFEKL pulsed splenocytes differentially labelled with CFSE. The specific lysis was assessed in the blood 24h later by flow cytometry.

HHS Vulnerability Disclosure